Page last updated: 2024-11-08

rocaglaol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rocaglaol: a cytotoxic cyclopenta(b)benzofuran from the bark of Aglaia crassinervia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AglaiagenusA plant genus of the family MELIACEAE. Members contain lariciresinol, pregnanes, insecticidal rocaglamide derivatives and other compounds.[MeSH]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID393602
CHEMBL ID468454
SCHEMBL ID750024
MeSH IDM0497869

Synonyms (15)

Synonym
rocaglaol
nsc695796
nsc-695796
(+/-)-rocaglaol
CHEMBL468454
(1r,3s,3ar,8bs)-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran-1,8b-diol
147059-46-9
SCHEMBL750024
(1r,3s,3ar,8bs)-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1h-cyclopenta[b]benzofuran-1,8b-diol
AKOS027323903
CCG-261725
CS-0016750
HY-N1342
8bh-cyclopenta[b]benzofuran-1,8b-diol, 1,2,3,3a-tetrahydro-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, (1r,3s,3ar,8bs)-
FS-10391

Research Excerpts

Overview

Rocaglaol is a cytotoxic cyclopenta[b]benzofuran isolated from the bark of Aglaia crassinervia.

ExcerptReferenceRelevance
"Rocaglaol is a cytotoxic cyclopenta[b]benzofuran isolated from the bark of Aglaia crassinervia. "( Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells.
Chai, H; Cordell, GA; Farnsworth, NR; Kinghorn, AD; Mi, Q; Su, BN; Swanson, SM,
)
3.02

Treatment

ExcerptReferenceRelevance
"Rocaglaol treatment induced Bax expression through 12 to 72 h of exposure, while Bcl-xl expression was slightly decreased through 48 h, and decreased more significantly by 72 h."( Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells.
Chai, H; Cordell, GA; Farnsworth, NR; Kinghorn, AD; Mi, Q; Su, BN; Swanson, SM,
)
2.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor p65Homo sapiens (human)ED500.00500.00500.04250.0800AID733967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID1100805Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID733969Cytotoxicity against human HT-29 cells2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID430792Cytotoxicity against human KB cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430804Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID379690Cytotoxicity against mouse WEHI164 cells2000Journal of natural products, Apr, Volume: 63, Issue:4
Flavonol-cinnamate cycloadducts and diamide derivatives from Aglaia laxiflora.
AID1100804Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID354876Growth inhibition of mouse NIH/3T3 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430798Inhibition of P-glycoprotein expressing human MCF7 cells assessed as change in rhodamine 123 efflux at 0.1 to 1 uM2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430794Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430808Cell cycle arrest in human HL60 cells assessed as increase in G0/G1 peak at 200 nM after 48 hrs by FACS analysis2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354869Induction of morphological changes in rat NRK cells expressing K-ras assessed as flat morphology and cytoskeletal organization at 10 to 30 ng/mL after 1 day1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430797Cytotoxicity against human HL60 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354867Inhibition of RNA synthesis in rat NRK cells expressing K-ras assessed as [5-3H]uridine incorporation after 1 hr1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID379691Cytotoxicity against mouse LL/2 cells2000Journal of natural products, Apr, Volume: 63, Issue:4
Flavonol-cinnamate cycloadducts and diamide derivatives from Aglaia laxiflora.
AID1100802Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination at 200 ug/ml by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID354875Growth inhibition of rat NRK cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430795Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID379692Cytotoxicity against mouse P388 cells2000Journal of natural products, Apr, Volume: 63, Issue:4
Flavonol-cinnamate cycloadducts and diamide derivatives from Aglaia laxiflora.
AID733968Cytotoxicity against human CCD-112CoN cells2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID430796Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430800Induction of apoptosis in rat H9c2 cells at 0.5 to 50 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354868Decrease in cellular Ras protein level in rat NRK cells expressing K-ras at 2.5 ng/mL after 1 to 3 days by immunoblotting1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID354874Growth inhibition of mouse NIH/3T3 cells expressing N-ras1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430818Antiproliferative activity against human HL60 cells at 50 nM in presence of necroptosis inhibitor 3-methyladenine2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID448438Inhibition of NF-kappaB activation2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
The first pharmacophore model for potent NF-kappaB inhibitors.
AID1100803Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID430799Enhancement of doxorubicin-induced cytotoxicity against human HepG2 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430811Induction of apoptosis in human HL60 cells assessed as caspase 3/7-mediated DEVD-AMC substrate cleavage at 1 to 1000 nM after 48 hrs by spectroscopy2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430817Antiproliferative activity against human HL60 cells at 50 nM in presence of autophagy inhibitor necrostatin 12009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430793Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID733967Inhibition of NF-kappaB p65 (unknown origin) by ELISA2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID354872Growth inhibition of mouse NIH/3T3 cells expressing K-ras1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430807Cell cycle arrest in human HL60 cells assessed as accumulation of cells in G2/M phase at 20 nM after 48 hrs by FACS analysis2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354870Induction of morphological changes in rat NRK cells expressing K-ras assessed as flat morphology and cytoskeletal organization at 10 to 30 ng/mL after 3 days1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430806Cell cycle arrest in human HL60 cells assessed as accumulation of cells in G2/M phase at 200 nM after 48 hrs by FACS analysis2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354866Inhibition of DNA synthesis in rat NRK cells expressing K-ras assessed as [methyl-3H]thymidine incorporation after 1 hr1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430816Antiproliferative activity against human HL60 cells at 50 nM in presence of caspase inhibitor Z-VAD-FMK2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID430819Inhibition of proteasome activity in human HL60 cells at 20 to 200 nM2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID354873Growth inhibition of mouse NIH/3T3 cells expressing H-ras1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID354865Inhibition of protein synthesis in rat NRK cells expressing K-ras assessed as L-[4,5-3H]leucine incorporation after 1 hr1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID354871Growth inhibition of rat NRK cells expressing K-ras1996Journal of natural products, Jul, Volume: 59, Issue:7
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.
AID430809Cell cycle arrest in human HL60 cells assessed as increase in G0/G1 peak at 20 nM after 48 hrs by FACS analysis2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's6 (50.00)29.6817
2010's3 (25.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]